Origin Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Origin Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-14,227	Closed	-$265K	–	25
2022 Q4	$265K	Sell	14,227 -11,253	-44%	-$173K	0.08%	11
2022 Q3	$327K	Sell	25,480 -6,091	-19%	-$72.2K	0.13%	8
2022 Q2	$221K	Sell	31,571 -10,722	-25%	-$78.6K	0.11%	22
2022 Q1	$351K	Sell	42,293 -12,325	-23%	-$87.1K	0.12%	16
2021 Q4	$369K	Hold	54,618	–	–	0.09%	23
2021 Q3	$289K	Hold	54,618	–	–	0.07%	27
2021 Q2	$314K	Buy	+54,618	New	+$282K	0.04%	115

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JAM

Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Origin Asset Management's CPRX Position: Q1 2023 in Review

Origin Asset Management sold out of Catalyst Pharmaceutical (CPRX) in Q1 2023, closing a stake of 14,227 shares — an estimated $265K sold.

Origin Asset Management first reported a position in CPRX in Q2 2021 and held it in 7 quarters. The position peaked at $369K in Q4 2021. 259 funds tracked by Wall St. Rank hold CPRX as of Q1 2023.

Origin Asset Management reported no remaining Catalyst Pharmaceutical position as of Q1 2023 after selling out during the quarter.
Origin Asset Management sold 14,227 Catalyst Pharmaceutical shares in Q1 2023, an estimated $265K.
Origin Asset Management first reported a position in Catalyst Pharmaceutical in Q2 2021 and held it in 7 quarters.
Origin Asset Management's Catalyst Pharmaceutical position peaked at $369K in Q4 2021.
259 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2023.

Based on Origin Asset Management's 13F filing for Q1 2023, filed 12 May 2023.